Cresten Labs sells only through crestenlabs.eu and orders@crestenlabs.eu. Any other site or social account using our name is not us.
Skip to main content
Research Use Only, not for human or veterinary consumption Ships across the EU single market Verified, every batch
Cart 0
CompoundBPC-157, fifteen-amino-acid peptide CategoryTissue Repair EditionCresten Labs Editorial, 2026
Research Use Only declaration

This compound is supplied for in-vitro and preclinical research only. It is not a medicinal product. It is not approved for human or veterinary use in any jurisdiction. No therapeutic, medicinal, cosmetic, or performance-enhancement claims are made or implied. By proceeding to inquire, you confirm you are an adult researcher acquiring this compound within your own research framework. Full terms on the Research Use Only page.

Tissue Repair, Fifteen-amino-acid peptide

BPC-157

10 mg freeze-dried vial. Also written BPC 157 (space) or BPC157. Body Protection Compound 157

Janoshik verified ISO/IEC 17025 COA pre-published Research use only
180+ PubMed-indexed publications cite BPC-157 in preclinical and in-vitro literature. View bibliography on PubMed →
Every batch tested for HPLC purity by Janoshik before it ships. You receive the certificate for your batch with your order.
How verification works →
€78.99 In stock, ships within 24h
One acknowledgement step before submission. Inquiry sent to our research desk by email. Confirmation, payment, and dispatch handled directly. EU shipping only.
Certificate format Specimen
Bulk pricing: 5+ 5%, 10+ 10%, 25+ 15%, institutional accounts contact for tendered pricing
Research account standing. Cumulative orders across four rolling quarters trigger pricing tiers (Researcher 5%, Senior Researcher 7.5%, Principal Investigator 10%) applied automatically at checkout.
View standing program →
Custom quote, single or multi-compound Submit a request for quotation Custom quantities, vial-size variants, multi-compound orders, institutional accounts. Quote turnaround typically two to five business days.
Technical specifications · BPC-157 Cresten Labs reference catalogue

Compound specifications, chemistry, and storage.

Technical specifications

Specimen format
Compound nameBPC-157 (Body Protection Compound 157)
Also known asBPC, Body Protection Compound, pentadecapeptide BPC-157, gastric pentadecapeptide, PL 14736, bepecin, Booly
CAS number137525-51-0
PubChem CID9941957
InChI KeyRJEZTFGTVHHTAH-RABKVUJESA-N
SMILESCC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)CN)C(=O)O
Empirical formula (Hill notation)C₆₂H₉₈N₁₆O₂₂
Molecular weight1419.55 g/mol (monoisotopic mass: 1418.67)
Salt formAcetate (default)
Counter-ion contentQuantified per batch on COA. Custom salt forms (chloride, ammonium, TFA) available on quote.
Sequence (1-letter)GEPPPGKPADDAGLV
Sequence (3-letter)Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Length15 amino acids (fifteen-amino-acid peptide)
Weight basisGross weight per industry standard. Net peptide content quantified on batch COA.
Quantity per vial10 mg
FormatFreeze-dried white powder or thin film, sealed under inert atmosphere. Why does the vial look empty?
AppearanceWhite freeze-dried cake or powder. May also appear as a thin film on the vial wall.
SolubilityWater soluble, reconstituted with bacteriostatic water (1 to 2 ml typical)
Solution colourClear and colourless when correctly reconstituted
Purity (HPLC)Specification ≥99.0%, tested before listing
Identity confirmationLC-MS, batch-specific spectrum on COA
Endotoxin (LAL)Within Ph. Eur. specification, batch report on COA
Storage (freeze-dried)2 to 8 degrees Celsius, sealed, protected from light. Avoid thermal cycling.
Storage (reconstituted)2 to 8 degrees Celsius. Use within 4 to 6 weeks. Avoid repeated freeze-thaw.
Shelf life24 months from synthesis date when storage conditions are maintained
Country of synthesisEU partner facility, Ph. Eur. methodology references
ApplicationIn-vitro and preclinical research only. Not for human or veterinary use.
Research Use Only Supplied for in-vitro and preclinical laboratory research only. Not for human or veterinary use. Cresten Labs does not provide therapeutic or dosing guidance.
Compound monograph · BPC-157 · tissue repair Cresten Labs Editorial, 2026

A fifteen-amino-acid peptide, and what the published research says about it.

BPC 157 is a synthetic fifteen-amino-acid peptide, and it is the most-requested compound we supply. It came out of an unlikely place: a protein the body keeps in its own stomach lining. Three decades of published work have followed it since, almost all of it in animal and laboratory models. What follows is the part we can stand behind, what the compound is, where it came from, what the literature actually examines, and what the certificate confirms. What it does in a body is not ours to tell you. That belongs to the research, and we link the research.

Where BPC-157 comes from.

Here is the part most buyers do not know. BPC 157 is not a designed molecule. It is a fragment of something the human body already makes. In the early 1990s, researchers isolated a protective protein from human gastric juice, the fluid the stomach uses to defend its own lining against the acid it produces. That protein is called body protection compound. BPC 157 is the fifteen-amino-acid stretch of it that carried the activity the original group was chasing. The 157 is not a batch code or a catalogue number. It is the position of those residues in the parent sequence. So when you reconstitute a vial, you are working with a copy of a fragment the body evolved to protect itself. That origin is most of why the research community kept looking.

The version in the vial is made the way every serious research peptide is made: built one amino acid at a time on a solid support by Fmoc solid-phase synthesis, then purified by HPLC until the main peak is clean. After that it is freeze-dried and sealed under inert atmosphere, which is why it arrives as the thin film described above and stays stable at room temperature in transit. It only wants cold once you have reconstituted it. Bacteriostatic water at the bench, and it goes into solution clear and colourless if it is what it should be. If it does not, that tells you something too.

The literature is unusually deep for a compound this size. PubMed carries more than 180 papers naming BPC 157 as of 2026, the large majority animal and in-vitro work, with a small number of early human studies. That depth is why it sits at the front of our catalogue and why the SERPs for it are full of vendors who never tested a batch. We took the opposite approach, and we compare ourselves against them openly. The research is real and you can read it; the verification is the part most vendors skip, and that is the part we built the company around. There is a second reason BPC 157 specifically attracts bad supply. It is the compound newcomers reach for first, which means it is the one most often sold by operators who count on buyers not knowing how to check. A clean-looking vial and a generic PDF are enough to close an inexperienced researcher. They are not enough to close anyone who has read this far. The fifteen-residue identity is verifiable by mass, the purity is verifiable by HPLC, and the batch is traceable to the lab that ran both. With BPC 157 more than almost any other compound, the question is not whether you can find it. It is whether you can trust the vial in your hand, and that is a question with a documented answer here.

What the research looks at.

The research on how BPC 157 works covers several pathways. Studies have looked at how the peptide affects new blood vessel formation, including its interaction with a receptor called VEGFR2 in animal studies of small blood vessel response. Other studies have looked at the peptide's role in nitric oxide pathways, including effects on an enzyme called eNOS in animal studies of blood vessel function.

Research has also looked at fibroblast and tendon biology in cell culture and animal studies. Papers have examined fibroblast movement and collagen organisation, with work in animal models of tendon injury. The research is consistent in describing the peptide as a signal that triggers other steps, rather than something that acts directly on cells. The exact receptor interactions are still not fully mapped in the published research.

"The peptide's exact receptor interactions are still not fully mapped in the published research."

Research on the gut and stomach is the largest single category of BPC 157 work. Since the compound was first found in stomach fluid, a large body of animal research looks at stomach lining protection, ulcer healing rates, and small blood vessels in the gut. The research in this area is the most developed and the most cited.

Where the published research does not go: there are no large randomised controlled trials in humans. There are no FDA or EMA approvals for any medical use. The compound is classified as a research compound, and research is the only context in which it is supplied.

Analytical characterisation

What the certificate confirms.

Every Cresten batch of BPC 157 ships with a certificate from an analytical lab, against the test panel described on the Methodology page. The certificate that ships with your batch confirms:

HPLC purity
main-peak percentage by area at 220 nm, gradient elution, dominant peak. Specification: minimum 98%.
LC-MS identity
Confirmed. Observed mass matches the theoretical 1419.55 g/mol for BPC-157 within instrument tolerance, which is the single clearest way to confirm the right peptide is in the vial and not a cheaper, lighter substitute.
Endotoxin (LAL)
Below detection limit. Specification: less than 5 EU/mg per Ph. Eur. 2.6.14.
Bioburden
Below detection limit per Ph. Eur. 2.6.12 microbial enumeration.
Report on file
Janoshik Analytical (batch certificate of analysis supplied with your order)

The certificate format is shown on the batch verification page.

You have seen how the batch is verified. Ordering opens with the batch certificate. Send an enquiry and we reply with current batch detail.
Enquire about this batch →
Cited research

Selected published research on BPC-157.

Monograph last reviewed 26 May 2026 · references checked against PubMed

The references below are a small selection from the wider published research. Each one can be checked on PubMed using the PMID number listed.

PMID 27036592
Sikiric, P., et al. (2016). Brain-gut axis and fifteen-amino-acid peptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 14(8), 857-865.
PMID 21030672
Chang, C.H., et al. (2011). The promoting effect of fifteen-amino-acid peptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780.
PMID 19386053
Sikiric, P., et al. (2009). Fifteen-amino-acid peptide BPC 157 positively affects both non-steroidal anti-inflammatory drug-induced gastrointestinal lesions and adjuvant arthritis in rats. Journal of Physiology Paris, 103(1-3), 286-296.
PMID 32393608
Seiwerth, S., et al. (2020). BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 26(11), 1230-1244.
PMID 28218077
Hsieh, M.J., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333.
PMID 29951172
Gwyer, D., et al. (2018). Gastric fifteen-amino-acid peptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153-159.

Citation note: each PMID resolves to PubMed at ncbi.nlm.nih.gov/pubmed/{PMID}. The references above are a small selection from the wider published research.

What this monograph is not

This monograph summarises what the published research looks at regarding BPC 157 mechanism. It is not a therapeutic recommendation. It is not dosing guidance. It is not a clinical protocol. It is not medical advice.

Cresten Labs supplies BPC 157 as a research compound for lab-based research only. The decision to investigate any compound in any research framework is the researcher’s decision, within their own ethical, legal, and methodological boundaries.

Cresten makes no claim about human therapeutic use, no claim about clinical effectiveness, no claim about safety in human use, and no claim that this compound has been reviewed by any regulator for any medical use.

Researcher questions

Frequently asked questions about BPC-157

Common research-protocol and supply questions about BPC 157, with answers grounded in published peer-reviewed research and Cresten Labs supply practice. All information is for in vitro and preclinical research only.

What is BPC-157?

BPC 157 is Body Protection Compound 157, a 15-amino-acid peptide (CAS 137525-51-0, molecular weight 1419.556 g/mol). Cresten Labs supplies BPC 157 as a freeze-dried vial for in vitro and preclinical research only, with each batch verified at Janoshik Analytical.

What does research suggest BPC-157 does?

Published research investigates BPC 157 for directing endothelial cell migration and capillary sprouting toward damaged tissue in preclinical models. The compound is studied primarily in soft tissue and gastrointestinal mucosa research. BPC 157 is supplied for research use only and is not approved by any regulator for medical use.

What is the typical BPC-157 dosage in published research?

Published BPC 157 dosage in research protocols ranges from 100 to 500 mcg per administration, administered subcutaneously, with daily dosing for 4 to 6 weeks in tendon and gut repair studies. Cresten Labs publishes the typical BPC 157 protocol ranges as research-protocol references only; this is not dosing guidance for human use.

How do I reconstitute BPC-157 for research?

Standard BPC 157 reconstitution adds 2 mL plain bacteriostatic water for the 10 mg vial. Cresten ships lyophilized BPC-157 vials for reconstitution by the researcher per their protocol.

What is the BPC-157 half-life and how is BPC-157 storage handled?

Published research reports BPC 157 systemic half-life at approximately 4 hours systemic. BPC 157 storage: lyophilized vial stable at room temperature for shipping; reconstituted solution stored at 2 to 8 °C and used within 28 days. The Cresten certificate of analysis lists the synthesis date, batch identifier, and the storage conditions verified for this specific batch.

BPC-157 vs TB-500: how do they compare in research?

In published research comparing BPC 157 vs TB-500, BPC 157 acts on capillary growth, TB-500 on actin polymerization; the two operate on complementary repair pathways in the published preclinical literature. The two compounds are studied separately and in combination depending on the research question. Cresten Labs supplies both as verified research compounds.

What does research literature report about BPC-157 side effects?

Published BPC 157 research reports the following: preclinical studies report a benign side-effect profile in animal models; human safety data is limited because no regulator has approved BPC 157 for medical use anywhere. Cresten Labs supplies the compound for research use only; clinical-use side-effect data should be drawn from peer-reviewed clinical trial publications, not from research-vendor pages.

Where to buy BPC-157 in Europe?

Cresten Labs supplies BPC 157 across the EU single market to 16 European countries. Each BPC 157 batch is tested at Janoshik Analytical with the certificate of analysis published on the website before it lists. BPC-157 is sold for in vitro and preclinical research only, not for human or veterinary use.

How is BPC-157 verified at Cresten Labs?

Every BPC 157 batch is tested at Janoshik Analytical in Czech Republic, an third-party peptide-analysis laboratory. Each batch certificate documents HPLC purity, mass-spectrometry identity confirmation, and contamination panels. The certificate publishes with the batch, before it lists.

What is the typical BPC-157 stack in published research?

In published research, the typical BPC 157 stack pairs the compound with TB-500. BPC 157 acts on capillary growth, TB-500 on actin polymerization; the two operate on complementary repair pathways in the published preclinical literature.